BioCatalyst

40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks — catalyst calendar

1 verified catalyst event(s) referencing 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-01 (month)
in 3mo
ESTIMATED
 READOUT
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in
Phase 3 · Focal Epilepsy
 PRAX Praxis Precision Medicines, 40 mg/day vormatrogine for 12 weeks, 30 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.